{"filing":{"accession_number":"0001104659-26-071211","cik":"0001638287","ticker":"MTVA","company_name":"MetaVia Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"mtva-20260608x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1638287/000110465926071211/mtva-20260608x8k.htm"},"events":[{"id":6129,"run_id":5380,"accession_number":"0001104659-26-071211","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"MetaVia disclosed presentation of new Phase 1 clinical data for its lead obesity and metabolic disease candidates (DA-1726 and DA-1241) and preclinical combination data for vanoglipel at the ADA 2026 Scientific Sessions, showing statistically significant body weight reductions (6.1–9.1%) and favorable safety profiles. These positive interim clinical and preclinical results would materially affect investor assessment of the company's drug development trajectory and competitive position in the obesity/metabolic disease space.","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5095,"accession_number":"0001104659-26-071211","item_number":"7.01","item_title":"Regulation FD Disclosures.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MetaVia disclosed presentation of new Phase 1 clinical data for its lead obesity and metabolic disease candidates (DA-1726 and DA-1241) at a major scientific conference (ADA 2026 Scientific Sessions). While this is clinical/pipeline progress rather than a traditional earnings release or executive event, the disclosure of new higher-dose cohort results and preclinical combination data for novel therapeutics would materially affect investor assessment of the company's drug development trajectory and competitive position in the obesity/metabolic disease space. The Item 7.01 Regulation FD classification and boilerplate language do not diminish the materiality of the underlying clinical milestone announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T13:04:12.351569+00:00","company_name":"","ticker":null,"filing_date":""},{"id":5096,"accession_number":"0001104659-26-071211","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MetaVia disclosed late-breaking clinical and preclinical data for its obesity and metabolic disease pipeline (DA-1726 and vanoglipel) presented at the ADA 2026 Scientific Sessions. The DA-1726 Phase 1 data showed statistically significant body weight reductions (6.1–9.1%) and favorable safety, while vanoglipel combination studies demonstrated synergistic effects in preclinical MASH and metabolic models. These positive interim results would reasonably affect investor assessment of the company's pipeline progress and clinical prospects, but the disclosure does not fit neatly into earnings_release (no financial results), material_impairment, or other more specific event categories—making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T13:04:12.351569+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5095,"accession_number":"0001104659-26-071211","item_number":"7.01","item_title":"Regulation FD Disclosures.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MetaVia disclosed presentation of new Phase 1 clinical data for its lead obesity and metabolic disease candidates (DA-1726 and DA-1241) at a major scientific conference (ADA 2026 Scientific Sessions). While this is clinical/pipeline progress rather than a traditional earnings release or executive event, the disclosure of new higher-dose cohort results and preclinical combination data for novel therapeutics would materially affect investor assessment of the company's drug development trajectory and competitive position in the obesity/metabolic disease space. The Item 7.01 Regulation FD classification and boilerplate language do not diminish the materiality of the underlying clinical milestone announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T13:04:12.351569+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-06-08"},{"id":5096,"accession_number":"0001104659-26-071211","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"MetaVia disclosed late-breaking clinical and preclinical data for its obesity and metabolic disease pipeline (DA-1726 and vanoglipel) presented at the ADA 2026 Scientific Sessions. The DA-1726 Phase 1 data showed statistically significant body weight reductions (6.1–9.1%) and favorable safety, while vanoglipel combination studies demonstrated synergistic effects in preclinical MASH and metabolic models. These positive interim results would reasonably affect investor assessment of the company's pipeline progress and clinical prospects, but the disclosure does not fit neatly into earnings_release (no financial results), material_impairment, or other more specific event categories—making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T13:04:12.351569+00:00","company_name":"MetaVia Inc.","ticker":"MTVA","filing_date":"2026-06-08"}]}